Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function - Wikidata - wikimedia - TriplyDB

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

http://www.wikidata.org/entity/Q34015423

about

Immunologic aspect of ovarian cancer and p53 as tumor antigen.Autophagy in malignant transformation and cancer progression Mutations in the DNA-binding domain of the transcription factor Bright act as dominant negative proteins and interfere with immunoglobulin transactivation Suppression of induced pluripotent stem cell generation by the p53-p21 pathway Akt3 is responsible for the survival and proliferation of embryonic stem cells A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells.Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma.Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis.p53-mediated hematopoietic stem and progenitor cell competition.Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.Mouse models for the p53 R72P polymorphism mimic human phenotypes p53 and ATF4 mediate distinct and additive pathways to skeletal muscle atrophy during limb immobilization.Crippling p53 activities via knock-in mutations in mouse models.The interplay of NR4A receptors and the oncogene-tumor suppressor networks in cancer Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.Analysing p53 tumour suppressor functions in mice.A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect.TP53-Associated Pediatric Malignancies.p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome.Mouse models with modified p53 sequences to study cancer and ageing.p53-dependent activation of microRNA-34a in response to etoposide-induced DNA damage in osteosarcoma cell lines not impaired by dominant negative p53 expression Gene transfer: Bax to the future for cancer therapy.The p53R172H mutant does not enhance hepatocellular carcinoma development and progression.Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.A new puzzling role of p53 in mouse embryonic stem cells.Sin3a is essential for the genome integrity and viability of pluripotent cells Targeted deletion reveals an essential function for the telomere length regulator Trf1.Germline HABP2 Mutation Causing Familial Nonmedullary Thyroid Cancer.MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.Initiation of prostate cancer in mice by Tp53R270H: evidence for an alternative molecular progression.Sex bias occurrence of hepatocellular carcinoma in Poly7 molecular subclass is associated with EGFR.Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma.Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.The pleiotropic phenotype of Apc mutations in the mouse: allele specificity and effects of the genetic background.Two hot spot mutant p53 mouse models display differential gain of function in tumorigenesis.Targeting prostate cancer based on signal transduction and cell cycle pathways.[The use of p53 as a tool for human cancer therapy].A conditional transposon-based insertional mutagenesis screen for genes associated with mouse hepatocellular carcinoma.How many mutant p53 molecules are needed to inactivate a tetramer?

P2860

Q24814703-C6E11811-8831-4F93-AD40-A76174815186 Q27000191-D41127CE-0938-4C15-A79A-FBCB0FAE2725 Q28507194-1CA9DEF5-CC73-4DB7-9582-F17F4ACC7D4C Q29619160-8F9BBEB7-5757-414A-8AFA-1233386B2F6B Q30491624-47763A1E-ED2F-4ACC-B124-5BA9F5C09AEA Q33591375-B49006B7-B0CC-4EA5-AE3F-1EC6CE9253BF Q33682960-AA9684D7-3670-4C05-8C90-EB57117329F3 Q33743767-EA6C903A-31F2-4E0D-B4D1-EAD3B247C730 Q33826589-FF9FBD27-93CF-4B09-A08A-51881BC9A9C7 Q33857597-4BDE7128-7BAF-46B6-B4F2-9856853E276A Q33926909-F3D61618-3353-4D78-B3CB-2CC9C7A2990E Q34001196-75C73E8E-40C3-4BA4-855F-F2047580783C Q34001316-C37CAE8E-003B-4025-A9F7-E065C5B385E5 Q34614596-06E873B6-147C-4857-9860-CEC3A2BD2D11 Q34771536-F055DFF4-60EE-4F1C-A123-CCB731E297A4 Q34898280-A7A4A74E-1BC8-4402-B061-405B4D834F35 Q35056035-D6B268AC-0DC6-44B6-B0DD-85B2B42C7D3C Q35099489-851B2879-D7AA-415D-91A1-C540AF467F16 Q35103165-15D1510A-109A-45D3-9526-746D5D874BF2 Q35103179-81122A00-896D-45AD-9DB7-06D9E3CE1423 Q35116669-0B5103B5-C7EC-4B33-9CC4-BD2D3A10180B Q35503066-72323D6E-7C56-4E0B-8669-7D551411A52C Q35596405-0E590605-239B-454F-8034-A51B198A5E1C Q35605993-6AE826BA-AA07-4026-9CAD-3A32642849A3 Q35648549-79A1E09A-32FE-4C60-9F8F-9045D5645633 Q35740692-9FBE3EEA-4413-4044-A1A2-7A92593806A9 Q35907694-7E3C7574-5078-4DEB-B6CF-3330230B3C0A Q35920252-ED12F35B-B23B-478F-977C-DAA945A46C76 Q36035930-EBFED813-6F4A-4C25-9DBE-1898308C384D Q36253975-04BCE24C-8240-400B-A162-02DE96AA5D17 Q36359259-86EFB620-E6EE-4D4E-B4BD-5BCC4DA64D52 Q36438132-B126FEEA-3B75-4389-8A7E-1254A934D483 Q36496709-43F6D37B-BD6E-47F4-BADD-7D71DCDAD3C8 Q36750166-27FF0AFB-22E9-4A44-8803-888C6683CC69 Q36873796-3CDE11DA-86D2-42BA-97E8-BC14B4BBEC56 Q36920797-33742436-7684-4909-99F1-0E0F2A944AFA Q36995054-1460C675-8CCB-4868-B6D0-7923DC0372F7 Q37081504-D288D0C6-F543-46B7-BE86-B3D7931724DA Q37266967-7485FEFD-3032-4C42-AF69-78527B648863 Q37278142-117622AF-2884-479C-9BB7-FA96184B6A0F

P2860

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

http://www.wikidata.org/entity/Q34015423

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Targeted point mutations of p5 ...... tion of wild-type p53 function

@ast

Targeted point mutations of p5 ...... tion of wild-type p53 function

@en

Targeted point mutations of p5 ...... tion of wild-type p53 function

@nl

type

label

Targeted point mutations of p5 ...... tion of wild-type p53 function

@ast

Targeted point mutations of p5 ...... tion of wild-type p53 function

@en

Targeted point mutations of p5 ...... tion of wild-type p53 function

@nl

prefLabel

Targeted point mutations of p5 ...... tion of wild-type p53 function

@ast

Targeted point mutations of p5 ...... tion of wild-type p53 function

@en

Targeted point mutations of p5 ...... tion of wild-type p53 function

@nl

P1433

Q34015423-F4059D7B-B515-42D4-9386-1E75F5AF83E8

P1476

Q34015423-D050FBE7-95E6-4546-A304-21CF7775D50F

P2093

Q34015423-00E91129-BE20-4055-A56F-EA077DF91F1C

Q34015423-04B6DA0F-7CAC-47F6-B043-EFFA40C49D47

Q34015423-307F7134-AF3D-405C-BB76-D6C12AA5267D

Q34015423-34377D02-CAAF-4A51-B2E8-DA4A7EF89879

Q34015423-ED7A0CA2-0ADA-4C00-9654-871506E3C4DB

Q34015423-EF87C3E3-86F6-4129-B677-2F128C17817A

P2860

Q34015423-0BA853E5-DB85-411D-A43D-DEF18ED25E3C

Q34015423-114802A5-2E7F-4FBE-9951-A2DD82C59F88

Q34015423-1827F0C3-E786-4C68-87B5-A1CF365BD711

Q34015423-1C5799A0-038B-4B54-A503-2BCBC77544D2

Q34015423-60E427CC-AA72-4675-91C3-0E0377B5150C

Q34015423-851CF1EF-BBE4-46A9-847E-1EAB4843079A

Q34015423-88AD78F3-5FF5-4D8A-9704-C046BC28F19B

Q34015423-897D9761-854E-43A0-BFAE-529EEBFF5FC6

Q34015423-8A309C6B-6499-4E14-A9C4-E1A805C55D0C

Q34015423-8B33FA6E-55A1-48DC-8791-BE879C42500F

P304

Q34015423-051EC480-630F-493E-87D6-79C089D6FA8E

P31

Q34015423-C72C97A9-ADB1-428C-B994-9C4B9869A022

P356

Q34015423-B5C9F657-FD13-4564-9F4F-74E31BB0E4C1

P407

Q34015423-6E5B495E-5918-49BA-8D76-8A65BE1047A1

P433

Q34015423-000B8754-0289-4D6B-9FF8-F8565B8FD992

P478

Q34015423-793E354C-7C38-45F7-B6F1-D8EB288A4EC6

P50

Q34015423-12BC91F0-8BA2-48E6-AB6C-A5D4D25405BF

P577

Q34015423-57250BC6-4FA5-41B8-BBAB-98CB05A85E93

P5875

Q34015423-C13705CA-F418-4086-900D-D8FDF0DB221D

P698

Q34015423-06166A81-B277-46CF-8B3F-A4FBE5604C6E

P932

Q34015423-B3697EF5-8B36-44E6-999E-53CA4576EE93

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Targeted point mutations of p5 ...... tion of wild-type p53 function

@en

P2093

Annemieke de Vries

http://www.w3.org/2001/XMLSchema#string

Barbara Miranda

http://www.w3.org/2001/XMLSchema#string

Conny Th M van Oostrom

http://www.w3.org/2001/XMLSchema#string

Elsa R Flores

http://www.w3.org/2001/XMLSchema#string

Harn-Mei Hsieh

http://www.w3.org/2001/XMLSchema#string

Tyler Jacks

http://www.w3.org/2001/XMLSchema#string

P2860

p53, the cellular gatekeeper for growth and division

Oncogenic forms of p53 inhibit p53-regulated gene expression

p53 mutations in human cancers

RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement

Tumor spectrum analysis in p53-mutant mice

p53: puzzle and paradigm

p53 is required for radiation-induced apoptosis in mouse thymocytes

The role of p53 in tumour suppression: lessons from mouse models.

High metastatic potential in mice inheriting a targeted p53 missense mutation.

RAG-2-deficient blastocyst complementation: an assay of gene function in lymphocyte development.

P304

2948-2953

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.052713099

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

P577

2002-02-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11493976

http://www.w3.org/2001/XMLSchema#string

P698

11867759

http://www.w3.org/2001/XMLSchema#string

P932

122453

http://www.w3.org/2001/XMLSchema#string